Chinese clinical oncology最新文献

筛选
英文 中文
One size does not fit all: the inclusion of carboplatin in neoadjuvant treatment of triple-negative breast cancer. 一种方法并不适用于所有:卡铂纳入三阴性乳腺癌的新辅助治疗。
IF 2.7 4区 医学
Chinese clinical oncology Pub Date : 2026-10-01 DOI: 10.21037/cco-2026-0056
Vishnu Prasath, Emily Cybulla, Aminatta Mitchell, Dionisia Quiroga
{"title":"One size does not fit all: the inclusion of carboplatin in neoadjuvant treatment of triple-negative breast cancer.","authors":"Vishnu Prasath, Emily Cybulla, Aminatta Mitchell, Dionisia Quiroga","doi":"10.21037/cco-2026-0056","DOIUrl":"https://doi.org/10.21037/cco-2026-0056","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 5","pages":"71"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Burden of sarcopenia and impact of structured physical programme in children with acute lymphoblastic leukaemia. 急性淋巴细胞白血病儿童肌肉减少症的负担和有组织的体育锻炼计划的影响。
IF 2.7 4区 医学
Chinese clinical oncology Pub Date : 2026-10-01 DOI: 10.21037/cco-2026-1-0003
Iris Y M Lim, Joanna Y L Tung, Anthony P Y Liu, Becky P K Tsang, Sarah W Y Poon, K S Ng, Stephen W W Chan, Frankie W T Cheng
{"title":"Burden of sarcopenia and impact of structured physical programme in children with acute lymphoblastic leukaemia.","authors":"Iris Y M Lim, Joanna Y L Tung, Anthony P Y Liu, Becky P K Tsang, Sarah W Y Poon, K S Ng, Stephen W W Chan, Frankie W T Cheng","doi":"10.21037/cco-2026-1-0003","DOIUrl":"https://doi.org/10.21037/cco-2026-1-0003","url":null,"abstract":"<p><strong>Background: </strong>Survival in paediatric acute lymphoblastic leukaemia (ALL) now exceeds 80%, yet treatment-related muscle loss may adversely affect functional outcomes. Data on sarcopenia in Asian paediatric ALL populations remain limited. This study aimed to determine the prevalence of low muscle mass in children with ALL at a tertiary paediatric center and to explore the feasibility of longitudinal muscle assessment within a small exercise pilot subgroup.</p><p><strong>Methods: </strong>This was a cross-sectional prevalence study with an embedded pilot feasibility case series. Children newly diagnosed with ALL in Hong Kong Children's Hospital between January 2022 and March 2024 were included in the prevalence cohort. Patients newly diagnosed between April and June 2024 were eligible for the pilot feasibility subgroup. Whole-body muscle mass was obtained from Dual-energy X-ray absorptiometry (DXA) scans. Muscle Mass Index (MMI) was calculated as whole-body lean mass divided by height squared (kg/m2). Sarcopenia was operationally defined as MMI z-score <-2 based on age- and sex-specific reference values. In the pilot subgroup, muscle mass, physical performance, bone mineral density (BMD), and trabecular bone score (TBS) were assessed at two fixed time points: within two months of diagnosis (T1) and four to six months post-diagnosis (T2). Participants completed an 8-week structured exercise program between assessments.</p><p><strong>Results: </strong>Seventy-six children were newly diagnosed during the study period; 24 underwent at least one DXA scan and were included in the prevalence analysis [mean age 10.8 years, interquartile range (IQR) 8 to 14 years; 58.3% male]. The prevalence of sarcopenia was 26%. In the six-patient pilot subgroup, all participants demonstrated low MMI and reduced muscle performance at baseline. The exercise program was completed without dropouts. Improvements in muscle mass and functional measures were observed between T1 and T2; however, the study was not powered to determine intervention efficacy.</p><p><strong>Conclusions: </strong>Sarcopenia is common among children with ALL in this single-center cohort. Larger prospective studies are needed to determine clinical implications and to evaluate structured exercise interventions in controlled settings.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 5","pages":"66"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A real-world observation on treatment patterns among Chinese patients with advanced esophageal cancer: a multicenter cross-sectional analysis. 中国晚期食管癌患者治疗模式的真实世界观察:多中心横断面分析。
IF 2.7 4区 医学
Chinese clinical oncology Pub Date : 2026-10-01 DOI: 10.21037/cco-2026-0078
Xianjun Zhao, Leilin Zhu, Jianzhuang Guo, Xianru Zhang, Hongwei Cai, Yong Wang, Ye Qian, Aiting Yan, Dongmei Ai, Jian Zhang, Zongtai Li, Zunbei Wen
{"title":"A real-world observation on treatment patterns among Chinese patients with advanced esophageal cancer: a multicenter cross-sectional analysis.","authors":"Xianjun Zhao, Leilin Zhu, Jianzhuang Guo, Xianru Zhang, Hongwei Cai, Yong Wang, Ye Qian, Aiting Yan, Dongmei Ai, Jian Zhang, Zongtai Li, Zunbei Wen","doi":"10.21037/cco-2026-0078","DOIUrl":"10.21037/cco-2026-0078","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Esophageal cancer (EC) remains a leading cause of cancer-related death in China, where most patients present with locally advanced or metastatic disease. Although immune checkpoint inhibitors have recently been incorporated into international treatment guidelines, real-world data describing how these agents are actually being adopted in Chinese practice settings remain scarce. Understanding current real-world treatment patterns is essential to inform clinical decision-making, treatment access, and future trial design. Therefore, this study aimed to characterize real-world systemic treatment patterns for advanced EC.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We retrospectively collected data on 322 patients with advanced EC (age ≥18 years) with complete electronic health records from six centers (5 were tertiary centers, and 1 was a secondary center) in China between January 1, 2022, and June 1, 2024; of these, the baseline and clinicopathological characteristics, number of previous treatment lines, regimens, and drugs were abstracted from electronic medical records, with treatment line determined by clinical history and expert consensus.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among the 322 patients included in the study (median age 69 years; age range 40-91 years; 71.4% male), squamous cell carcinoma was the predominant histological subtype (90.4%), while small-cell carcinoma accounted for only a small portion (3.9%). Systemic therapy was administered to 309 patients (96.0%) as first-line therapy and to 111 patients (34.5%) as second-line or later therapy. Chemotherapy was the most commonly administered first-line therapy (n=274, 88.7%), followed by immunotherapy (n=242, 78.3%). In the second-line or later setting, chemotherapy (n=85, 76.6%) and immunotherapy (n=82, 73.9%) remained predominant. Combination regimens were preferred for first-line chemotherapy (n=208, 75.9%), with the most common being taxane plus cisplatin (TP) (n=140, 51.1%). In the second-line or later setting, monotherapy (n=28, 32.9%) and TP regimens (n=24, 28.2%) were more common. Treatment selection varied significantly by age. Among patients aged 75-84 years, the proportion receiving single-agent chemotherapy was significantly higher than that receiving TP or fluorouracil plus cisplatin regimens (P=0.001), with significant differences in regimen selection observed across age groups overall (all P&lt;0.05). Treatment patterns also differed by histological subtype: patients with squamous cell carcinoma had the highest rates of both chemotherapy (89.4%) and immunotherapy (80.5%) use, while small-cell carcinoma was associated with exclusive use of platinum-based regimens (100%) and comparatively lower immunotherapy use (45.5%).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;These findings reveal real-world treatment patterns for advanced EC in China, suggesting that age-stratified treatment strategies and subtype-specific regimen selection should be considered in clinical decis","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 5","pages":"68"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic surgery for breast cancer liver metastases in the modern systemic therapy era: narrative review of evidence, patient selection, and a multidisciplinary decision framework. 现代全身治疗时代乳腺癌肝转移的肝手术:证据的叙述性回顾,患者选择和多学科决策框架。
IF 2.7 4区 医学
Chinese clinical oncology Pub Date : 2026-10-01 DOI: 10.21037/cco-2026-0085
José Ramón Oliver-Guillén, José Manuel Ramia, Mario Serradilla-Martín
{"title":"Hepatic surgery for breast cancer liver metastases in the modern systemic therapy era: narrative review of evidence, patient selection, and a multidisciplinary decision framework.","authors":"José Ramón Oliver-Guillén, José Manuel Ramia, Mario Serradilla-Martín","doi":"10.21037/cco-2026-0085","DOIUrl":"10.21037/cco-2026-0085","url":null,"abstract":"<p><strong>Background and objective: </strong>Breast cancer liver metastases (BCLM) usually represent systemic disease and are treated primarily with subtype-directed systemic therapy. Nevertheless, durable survival has been reported after hepatic resection in carefully selected patients. This narrative review critically appraises the contemporary evidence for surgery, distinguishes treatment effect from favorable selection, and proposes a practical multidisciplinary framework.</p><p><strong>Methods: </strong>PubMed/MEDLINE, the Cochrane Library, ClinicalTrials.gov, major guidelines, and reference lists were searched. English-language clinical studies, comparative cohorts, propensity-score analyses, systematic reviews, meta-analyses, randomized trials of metastasis-directed therapy, and guidelines published from January 2000 to June 2026 were prioritized; seminal earlier reports were retained when relevant.</p><p><strong>Key content and findings: </strong>No randomized trial has specifically shown that hepatectomy improves survival over modern systemic therapy. Retrospective surgical series report 5-year overall survival (OS) of approximately 30-60%, but recurrence is frequent. A reconstructed individual-patient-data meta-analysis of four propensity-matched studies associated surgery with improved OS (hazard ratio 0.40, 95% confidence interval: 0.32-0.51), while the contemporary LIBREAST registry reported 5-year OS and disease-free survival of 60% and 29%, respectively. These findings remain vulnerable to selection, immortal-time, referral, and treatment-era biases. Not all comparative studies show an independent survival effect once selection and confounding are addressed, and the magnitude of any causal benefit attributable to surgery itself remains uncertain. Randomized breast cancer trials of metastasis-directed therapy have not shown a clear progression-free survival or OS benefit, but local treatment was almost exclusively radiotherapy rather than surgery. The most credible surgical candidates have liver-limited or exceptionally controlled extrahepatic disease, low-volume completely treatable metastases, favorable or targetable biology, objective response or durable stability on systemic therapy, good performance status, and acceptable operative risk. Complete resection, parenchymal preservation, continued systemic therapy, and treatment in an experienced multidisciplinary program are central.</p><p><strong>Conclusions: </strong>Hepatic resection is not routine treatment for metastatic breast cancer. It is a selective component of multimodal care when disease biology, systemic control, technical resectability, and patient fitness converge. Prospective registries, target-trial emulation, molecular residual-disease studies, and ongoing randomized trials are needed to determine whether surgery is therapeutic or predominantly a marker of favorable biology.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 5","pages":"69"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between preoperative multidisciplinary team discussion and survival outcomes in patients with colorectal cancer liver metastases undergoing initial hepatic resection: a single-center retrospective cohort study. 一项单中心回顾性队列研究:术前多学科小组讨论与接受初始肝切除术的结直肠癌肝转移患者生存结局的关系
IF 2.7 4区 医学
Chinese clinical oncology Pub Date : 2026-10-01 DOI: 10.21037/cco-2026-0073
Yan Liu, Long Chen, Huachuan Song, Wei Cai, Ruipeng Song, Yongliang Zhang, Jizhou Wang
{"title":"Association between preoperative multidisciplinary team discussion and survival outcomes in patients with colorectal cancer liver metastases undergoing initial hepatic resection: a single-center retrospective cohort study.","authors":"Yan Liu, Long Chen, Huachuan Song, Wei Cai, Ruipeng Song, Yongliang Zhang, Jizhou Wang","doi":"10.21037/cco-2026-0073","DOIUrl":"https://doi.org/10.21037/cco-2026-0073","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Evidence regarding the association between multidisciplinary team (MDT) discussion and survival outcomes in patients with colorectal cancer liver metastases (CRLM) undergoing hepatic resection remains limited and inconsistent. This study aimed to evaluate the association between preoperative MDT discussion and survival outcomes in this surgically treated population.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We retrospectively analyzed consecutive patients with pathologically confirmed CRLM who underwent initial hepatic resection at our center between September 2020 and December 2024. Patients were categorized into MDT and non-MDT groups based on whether a preoperative MDT discussion was conducted. To improve balance in observed baseline characteristics, 1:1 propensity score matching (PSM) was performed. Overall survival (OS) was the primary endpoint, and recurrence-free survival (RFS) was analyzed as a secondary endpoint. Survival curves were estimated using the Kaplan-Meier method and compared with the log-rank test. Missing data were handled using multiple imputation (MI), and univariable and multivariable Cox regression analyses were performed to assess the association between MDT discussion and survival outcomes. Sensitivity analyses using complete-case multivariable Cox regression, Cox regression in the propensity score-matched cohort, and average treatment effect among the treated (ATT) weighting were performed to assess the robustness of the findings.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 256 patients were included, including 79 in the MDT group and 177 in the non-MDT group. After 1:1 PSM, 72 matched pairs were identified. Before PSM, the MDT group had significantly better OS than the non-MDT group (P=0.03). The 1- and 3-year OS rates were 97.2% and 77.9% in the MDT group, compared with 88.8% and 57.5% in the non-MDT group, respectively. After PSM, the difference in OS remained significant (P=0.01), with corresponding 1- and 3-year OS rates of 98.5% and 77.9% versus 85.3% and 49.1%, respectively. No significant difference in RFS was observed before (P=0.52) or after PSM (P=0.16). In MI-pooled univariable Cox regression analysis, MDT discussion was associated with improved OS [hazard ratio (HR): 0.541; 95% confidence interval (CI): 0.301-0.975; P=0.04], and this association remained significant in multivariable analysis (HR: 0.483; 95% CI: 0.260-0.897; P=0.02). MDT discussion was not independently associated with RFS in multivariable analysis (HR: 0.928; 95% CI: 0.654-1.317; P=0.67). Sensitivity analyses using complete-case multivariable Cox regression, Cox regression in the propensity score-matched cohort, and ATT weighting yielded generally consistent results with the primary analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Preoperative MDT discussion was associated with improved OS but not RFS in patients with CRLM undergoing initial hepatic resection. These findings support the potential value of MDT discussion i","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 5","pages":"65"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phosphaturic mesenchymal tumor-narrative review of the diagnostic challenges and modern treatment. 磷质间充质肿瘤的诊断挑战和现代治疗的叙述回顾。
IF 2.7 4区 医学
Chinese clinical oncology Pub Date : 2026-10-01 DOI: 10.21037/cco-2026-0079
Paulina Chmiel, Aneta Borkowska, Michał Wągrodzki, Irmina Michałek, Piotr Rutkowski, Mateusz Spałek
{"title":"Phosphaturic mesenchymal tumor-narrative review of the diagnostic challenges and modern treatment.","authors":"Paulina Chmiel, Aneta Borkowska, Michał Wągrodzki, Irmina Michałek, Piotr Rutkowski, Mateusz Spałek","doi":"10.21037/cco-2026-0079","DOIUrl":"https://doi.org/10.21037/cco-2026-0079","url":null,"abstract":"<p><strong>Background and objective: </strong>Phosphaturic mesenchymal tumor (PMT) is a very rare form of mesenchymal neoplasm. Its distinctive paraneoplastic syndrome, tumor-induced osteomalacia (TIO), significantly impacts patients' quality of life and results in long-term health consequences. PMTs frequently remain undiagnosed for extended periods due to the absence of specific manifestations and the imaging and clinical characteristics of the tumor itself. At present, there is an absence of clear management guidelines, and the extant literature on PMT is limited. The purpose of this paper is, therefore, to compile available data on PMT and TIO for clinicians.</p><p><strong>Methods: </strong>A narrative review was conducted, with a search of the PubMed, Web of Science and Scopus databases.</p><p><strong>Key content and findings: </strong>Recent advancements in the field of PMT have led to a more comprehensive understanding of the molecular mechanisms underlying tumor development. Specifically, the research has identified recurrent FN1-FGFR1 fusions as a major molecular driver of tumor development. Additionally, studies have highlighted the role of excessive fibroblast growth factor 23 (FGF23) production in disrupting phosphate homeostasis, resulting in osteomalacia, bone pain, fractures, and pseudofractures. Advanced functional imaging techniques remain crucial for PMT diagnosis, and the cornerstone of treatment is complete surgical resection, which is typically curative. However, the presentation of PMTs exhibits significant heterogeneity in clinical manifestations, histological characteristics, and imaging features. Clinicians often face challenges due to their limited experience with this very rare entity.</p><p><strong>Conclusions: </strong>This review synthesizes the clinical presentation, pathological features, diagnostic strategies, molecular pathogenesis, and therapeutic options for PMTs, emphasizing contemporary challenges and future investigative directions.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 5","pages":"70"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Duplicate trial populations and an ineligible combination regimen may undermine a meta-analysis of atezolizumab versus docetaxel. 重复的试验人群和不合格的联合方案可能会破坏atezolizumab与多西他赛的荟萃分析。
IF 2.7 4区 医学
Chinese clinical oncology Pub Date : 2026-10-01 DOI: 10.21037/cco-2026-0095
İvo Gökmen
{"title":"Duplicate trial populations and an ineligible combination regimen may undermine a meta-analysis of atezolizumab versus docetaxel.","authors":"İvo Gökmen","doi":"10.21037/cco-2026-0095","DOIUrl":"https://doi.org/10.21037/cco-2026-0095","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 5","pages":"72"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic comparison between male and female breast cancer: a population-based SEER database study. 男性和女性乳腺癌的预后比较:基于人群的SEER数据库研究。
IF 2.7 4区 医学
Chinese clinical oncology Pub Date : 2026-10-01 DOI: 10.21037/cco-2026-0088
Yong Chen, Hui Wang
{"title":"Prognostic comparison between male and female breast cancer: a population-based SEER database study.","authors":"Yong Chen, Hui Wang","doi":"10.21037/cco-2026-0088","DOIUrl":"https://doi.org/10.21037/cco-2026-0088","url":null,"abstract":"<p><strong>Background: </strong>Male breast cancer (MBC) is extremely rare. This research sought to analyze the distinctions in clinical features and prognostic outcomes between male and female breast cancer (FBC), and to further develop the nomogram to estimate overall survival (OS) among MBC patients.</p><p><strong>Methods: </strong>This study extracted data from the Surveillance, Epidemiology, and End Results (SEER) database. A total of 165,186 patients with a diagnosis of breast cancer between 2010 and 2015 were included according to predefined inclusion and exclusion criteria, comprising 163,821 FBC cases and 1,365 MBC cases. The chi-square test was employed to assess differences in clinical features between FBC and MBC. Kaplan-Meier analysis and propensity score matching (PSM) were utilized to evaluate differences in breast cancer-specific survival (BCSS) and OS. Cox proportional hazards models were applied to identify independent predictors of OS in MBC patients and these variables were subsequently used to develop a nomogram for predicting 3- and 5-year OS. Its performance and clinical utility were assessed with receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis (DCA).</p><p><strong>Results: </strong>MBC and FBC showed significant differences in clinical features. Kaplan-Meier analysis revealed that MBC exhibited inferior OS and BCSS compared with FBC. After PSM, MBC still had poorer OS compared with FBC, while BCSS was similar between the two groups. Multivariate Cox regression analysis identified age, marital status, race, grade, chemotherapy, and tumor size as independent predictors of OS in MBC patients. The nomogram was developed to estimate 3- and 5-year OS in MBC patients and showed strong predictive accuracy, as confirmed by ROC curves and calibration curves. Additionally, DCA indicated that the nomogram had favorable clinical utility.</p><p><strong>Conclusions: </strong>MBC has a poorer prognosis than FBC. The nomogram for estimating 3- and 5-year OS in MBC patients demonstrates good prognostic performance and may provide practical guidance for individualized clinical management.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 5","pages":"67"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic comparison between male and female breast cancer: a population-based SEER database study. 男性和女性乳腺癌的预后比较:基于人群的SEER数据库研究。
IF 2.7 4区 医学
Chinese clinical oncology Pub Date : 2026-08-31 DOI: 10.21037/cco-2026-0088
Yong Chen, Hui Wang
{"title":"Prognostic comparison between male and female breast cancer: a population-based SEER database study.","authors":"Yong Chen, Hui Wang","doi":"10.21037/cco-2026-0088","DOIUrl":"https://doi.org/10.21037/cco-2026-0088","url":null,"abstract":"<p><strong>Background: </strong>Male breast cancer (MBC) is extremely rare. This research sought to analyze the distinctions in clinical features and prognostic outcomes between male and female breast cancer (FBC), and to further develop the nomogram to estimate overall survival (OS) among MBC patients.</p><p><strong>Methods: </strong>This study extracted data from the Surveillance, Epidemiology, and End Results (SEER) database. A total of 165,186 patients with a diagnosis of breast cancer between 2010 and 2015 were included according to predefined inclusion and exclusion criteria, comprising 163,821 FBC cases and 1,365 MBC cases. The chi-square test was employed to assess differences in clinical features between FBC and MBC. Kaplan-Meier analysis and propensity score matching (PSM) were utilized to evaluate differences in breast cancer-specific survival (BCSS) and OS. Cox proportional hazards models were applied to identify independent predictors of OS in MBC patients and these variables were subsequently used to develop a nomogram for predicting 3- and 5-year OS. Its performance and clinical utility were assessed with receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis (DCA).</p><p><strong>Results: </strong>MBC and FBC showed significant differences in clinical features. Kaplan-Meier analysis revealed that MBC exhibited inferior OS and BCSS compared with FBC. After PSM, MBC still had poorer OS compared with FBC, while BCSS was similar between the two groups. Multivariate Cox regression analysis identified age, marital status, race, grade, chemotherapy, and tumor size as independent predictors of OS in MBC patients. The nomogram was developed to estimate 3- and 5-year OS in MBC patients and showed strong predictive accuracy, as confirmed by ROC curves and calibration curves. Additionally, DCA indicated that the nomogram had favorable clinical utility.</p><p><strong>Conclusions: </strong>MBC has a poorer prognosis than FBC. The nomogram for estimating 3- and 5-year OS in MBC patients demonstrates good prognostic performance and may provide practical guidance for individualized clinical management.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary study on efficacy and safety of pixantrone in relapsed/refractory aggressive B-cell lymphomas: multicenter, retrospective cohort study by Polish Lymphoma Research Group (PLRG). pixantrone治疗复发/难治性侵袭性b细胞淋巴瘤疗效和安全性的初步研究:波兰淋巴瘤研究小组(PLRG)开展的多中心、回顾性队列研究。
IF 2.7 4区 医学
Chinese clinical oncology Pub Date : 2026-08-13 DOI: 10.21037/cco-2026-1-0026
Magdalena Witkowska, Senastin Szmit, Agnieszka Kołkowska-Leśniak, Bartłomiej Kuszczak, Renata Kasza, Anna Koclęga, Oliwia Bachanek-Mitura, Dariusz Wołowiec
{"title":"Preliminary study on efficacy and safety of pixantrone in relapsed/refractory aggressive B-cell lymphomas: multicenter, retrospective cohort study by Polish Lymphoma Research Group (PLRG).","authors":"Magdalena Witkowska, Senastin Szmit, Agnieszka Kołkowska-Leśniak, Bartłomiej Kuszczak, Renata Kasza, Anna Koclęga, Oliwia Bachanek-Mitura, Dariusz Wołowiec","doi":"10.21037/cco-2026-1-0026","DOIUrl":"https://doi.org/10.21037/cco-2026-1-0026","url":null,"abstract":"<p><strong>Background: </strong>Pixantrone (PIX) is an anthracycline derivative with reduced cardiotoxicity, registered in Poland for monotherapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL) in the third or fourth line of treatment. As R/R population is difficult to treat due to comorbidities including circulatory system pathologies we evaluate polish patients treated with PIX. This is the first real life study evaluating patients treated with PIX in Poland with emphasis on efficacy and cardiovascular toxicity.</p><p><strong>Methods: </strong>The retrospective study assessing safety and effectiveness of PIX administered in patients with aggressive de novo or transformed B-NHL [according to the Revised European American Lymphoma (REAL) and World Health Organization (WHO) classifications], who relapsed or were refractory to two or three previous lines of chemotherapy regimens, including at least one standard anthracycline-based regimen. Patients who did not remain sensitive to anthracyclines were excluded from this study. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), complete response (CR) rate, overall response rate (ORR) and safety.</p><p><strong>Results: </strong>The data of 17 patients were collected in 6 study sites. The median age was 72 (range: 58-82) years old with male predominance (65%). In observed group10 patients had diffuse large B-cell lymphoma (DLBCL), 6 mantle cell lymphoma (MCL) and 1 patient had Richter syndrome. Five subjects responded to PIX (CR 2 and partial response 3)-ORR was 29%. The median of PFS was 12.9 months [standard error (SE) 2.2; 95% confidence interval (CI): 8.5, 17.2]. The median of survival time was 22.6 months (SE 7.3; 95% CI: 8.3, 36.8). The PIX compliance was good, with incidental dose omission or delay. The main reason for discontinuation was disease progression.</p><p><strong>Conclusions: </strong>Administration of PIX to patients with R/R aggressive B-NHL treated with multiple lines of chemotherapy containing maximal cumulative dose of anthracycline and with numerous concomitant diseases may be a potentially valuable therapeutic option but data from larger clinical studies will help in confirming PIX as an effective and safe option.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148807895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书